Contributor: Timothy D. Pineda
It is absolutely no secret how beneficial cannabis can be as a form of medicine. Like marijuana and brain cancer, for example. The way marijuana and brain tumors interact with one another is unlike any other medication on the market, and there is an abundance of scientific data to back up the fact that cannabinoids and brain tumors have a special relationship. That has been proven time and time again, through a litany of clinical trials and tests surrounding THC and brain cancer, specifically with glioblastoma cannabis treatments.
Studies Show Cannabis Can Help Those Suffering From Brain Cancer
However, our federal government continually placed cannabis in the Schedule One category of illegal substances decades ago, which prohibited labs and doctors across the country from studying cannabis as a potential form of medicine. This criminal miscategorization lumped marijuana in with the actually-lethal likes of hard, street drugs such as, cocaine and meth. And made the studying of cannabis oil for brain cancer an illegal act.
It was an abysmal decision on the part of our government, and it has prevented people from using cannabis for brain tumors for decades. The only reason anyone could even hypothesize as to why that happened, was money. Prescription pill makers are some of the greediest people on Earth. They provide opioids to the masses, promising a world of positive effects, when in reality, they are only making people’s lives worse.
Not only that, but these chemical-laden capsules are tremendously addictive, not to mention expensive. That sort of combination never leads to positive results, which is why thousands of Americans are losing their lives every single year due to opioid addictions and overdoses.
But, for one reason or another, these murderous pill companies are able to function as if nothing negative is associated with their products, and the government continues to look the other way, because “Big Pharma” lobbyists are routinely stuffing the pockets of most people on Capitol Hill. It’s a disgusting cycle of greed and bribery that would come to a sudden halt, if cannabis is legalized nationwide.
Lucky for us, avid cannabis enthusiasts, over the past decade we have seen major strides towards a total decriminalization of cannabis. When that inevitably happens, that’ll open up the flood gates to new research, and in doing so, we’ll eventually learn all there is to know about this multifaceted miracle plant. Because, to be honest, there’s a whole lot left to learn about cannabis, and its myriad of benefits.
And, while we wait for our stubborn politicians to change their minds, and do the right thing, we have no other choice but to look elsewhere for medical advancements in marijuana studies.
Like, in the UK, for example.
SEE ALSO: These Cannabis Strains Are Guaranteed To Make You Laugh
Across the pond there’s a veritable army of scientists and research groups who are spending every waking hour on cannabis research, all in hopes of figuring out how to best utilize its organic cannabinoids as a form of medicine. And there’s one company, in particular, who seems to be excelling in this field of marijuana research more than others.
They go by the name of GW Pharmaceuticals, and they are phenomenal at what they do.
Having been in the cannabis research game since 2007, these experts really know what they are talking about when it comes to implementing marijuana, and its various mediums, as a quality form of non-addictive medicine.
In the past, they have developed a cannabis-based drug that has dramatically helped children who suffer from seizures live more comfortable lives. And it looks like they have redirected their focus to potentially treating brain cancer patients with a series of cannabinoids, as well.
To be specific, they have concluded a second round of clinical trials for a cannabis-based treatment called, Glioma. This cannabinoid-filled treatment is specifically designed to help those who suffer from a seriously aggressive form of brain cancer known as, Glioblastoma Multiform, otherwise known as, GBM.
Over at GW, they conducted a study consisting of 21 patients who suffered from this debilitating disease. They then administered this treatment, which was a blend of various forms of CBD and THC. Of course, with every test of this nature, a placebo group was also utilized, in order to ensure that the data collected was as accurate as possible.
What they found was that a whopping 83% of the participants had a one-year rate of survival. This is significant, because typically, with people who suffer from this disease, that number is usually hovering around the 52% mark or so. Even more than that, this study found that, with this cannabinoid treatment, they were able to live roughly 550 days, as opposed to the 369 days that the placebo group experienced.
That sort of scientific finding is groundbreaking.
Though more studies and trials need to be conducted before anything is “set in stone,” the fact remains that cannabis is obviously responsible for an increase in well-being, even in people stricken with such a serious form of brain cancer. And, as you could probably imagine, this sort of scientific discovery caught the attention of many other experts in the field. And, while there was certainly a lot to talk about, most people were infatuated with the leader of the study, Susan Short.
Susan is the study’s principal investigator, as well as being an oncology professor at the prestigious Leeds Institute of Cancer and Pathology at St. James University Hospital. When Susan was reached for comment on this amazing data, she was more than happy to divulge a little more extrapolation on the study, itself.
Specifically, she said, “These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment.”
Now, to be fair, the entire study wasn’t a completely “smooth ride,” so to speak. There were many instances in which the participants of the study experienced a wealth of negative side effects. The likes of which included: dizziness, vomiting, and even constipation, among a list of other things.
This sort of occurrence is to be expected in clinical trials of this nature, and it’s how scientists know that they need to adjust the dosage to ensure that those sort of things don’t continue to happen in the future. It’s all about trial and error when it comes to scientific studies surrounding potential new forms of medicine, and these analytic tests surrounding cannabis are no different.
However, despite the minor bumps in the road, there were still a lot of positives to be taken away from this test, and hopefully, we will continue to see similar progress like this in the very near future.
